For the quarter ending 2026-03-31, RTGN had -$14,594 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -590,489 | -623,127 | -568,791 | -1,236,677 |
| Amortization of right of use asset | - | - | 640 | 1,281 |
| Stock-based compensation expense | 210,016 | 281,246 | 277,226 | 482,122 |
| Depreciation expense | - | 0 | 0 | 56 |
| Amortization of rou asset | 642 | 2,563 | - | - |
| Expenses allocated by sanovas on behalf of company | 165,375 | 165,375 | 165,375 | 330,750 |
| Increase in accounts payable and accrued liabilities | 104,757 | 47,131 | 20,947 | 94,602 |
| Decrease in lease liability | -474 | -446 | -194 | -348 |
| Increase in accrued interest | 960 | 960 | 960 | 1,920 |
| Total adjustments | 481,276 | 494,908 | 464,954 | 910,383 |
| Net cash (used in) operating activities | -109,213 | -128,219 | -103,837 | -326,294 |
| Proceeds from exercise of stock options and warrants | - | - | - | 0 |
| Proceeds from sale of common stock | - | 212,000 | 100,000 | 86,000 |
| Advances from related parties, net | - | -69,099 | 3,090 | 85,073 |
| Proceeds from collection of stock subscription receivable | 125,000 | 0 | 0 | 150,000 |
| Advances from related parties, net | -30,381 | - | - | - |
| Net cash provided by financing activities | 94,619 | 142,901 | 103,090 | 321,073 |
| Net (decrease) in cash | -14,594 | 14,682 | -747 | -5,221 |
| Cash at beginning of period | 14,774 | 92 | 6,060 | - |
| Cash at end of period | 180 | 14,774 | 92 | - |
RetinalGenix Technologies Inc. (RTGN)
RetinalGenix Technologies Inc. (RTGN)